Trial Profile
Phase II Study of Rituximab Plus MG4101 in Patients With Relapsed or Refractory Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 01 Nov 2022
Price :
$35
*
At a glance
- Drugs MG 4101 (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 24 Oct 2022 Status changed from active, no longer recruiting to discontinued.
- 04 Feb 2022 Planned primary completion date changed from 1 Jan 2022 to 4 Apr 2022.
- 22 Sep 2021 Planned primary completion date changed from 1 May 2021 to 1 Jan 2022.